The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer

PARTNER is a prospective, phase II–III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer1, 2, who were germline BRCA1 and BRCA2 wild type3. Here we report the results of the trial. Patients (n = 559) were randomized on a 1:1 basis to receive neoadjuvant...

Full description

Bibliographic Details
Main Authors:	Abraham, JE, Pinilla, K, Dayimu, A, Grybowicz, L, Demiris, N, Harvey, C, Drewett, LM, Lucey, R, Fulton, A, Roberts, AN, Worley, JR, Chhabra, A, Qian, W, Vallier, A, Hardy, RM, Chan, S, Hickish, T, Tripathi, D, Venkitaraman, R, Persic, M, Aslam, S, Glassman, D, Raj, S, Borley, A, Levitt, NC
Format:	Journal article
Language:	English
Published:	Nature Research 2024

The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer

Similar Items